Clinical data | |
---|---|
Trade names | Ketanest, Spravato, Vesierra, others |
Other names | Esketamine hydrochloride; (S)-Ketamine; S(+)-Ketamine; JNJ-54135419 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a619017 |
License data |
|
Dependence liability | Low–moderate (physical); high (psychological) [1] |
Routes of administration | Intranasal [1] |
Drug class | NMDA receptor antagonist [1] |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C13H16ClNO |
Molar mass | 237.73 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Esketamine, sold under the brand name Spravato among others, is a medication used for treatment-resistant depression or depression with acute thoughts of suicide. [1] [4] It; however, appears to be less effective than ketamine. [6] It may also be used for anesthesia and pain. [7] It is used as a nasal spray or by intravenous injection. [1] [7] In depression benefits generally occur within 24 hours. [1]
Common side effects include dissociation, dizziness, sedation, headache, anxiety, vomiting, and increased blood pressure. [1] Other side effects may include misuse. [4] The compound is the S(+) enantiomer of ketamine. [8] Use when breastfeeding is not recommended. [9] It primarily acts by blocking N-methyl-D-aspartate (NMDA) receptors. [1]
Esketamine came into medical use in Germany in 1997. [10] [11] It was approved for medical use in the United States and Europe in 2019. [8] [12] It is available as a generic medication. [13] In the United States the nasal spray costs about 5,500 to 7,900 USD for the first month of treatment as of 2021. [14] [4] The intravenous formulation in the United Kingdom costs the NHS about £26 for 10 vials of 50 mg each. [7]
{{
cite book}}
: CS1 maint: date format (
link)
Clinical data | |
---|---|
Trade names | Ketanest, Spravato, Vesierra, others |
Other names | Esketamine hydrochloride; (S)-Ketamine; S(+)-Ketamine; JNJ-54135419 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a619017 |
License data |
|
Dependence liability | Low–moderate (physical); high (psychological) [1] |
Routes of administration | Intranasal [1] |
Drug class | NMDA receptor antagonist [1] |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C13H16ClNO |
Molar mass | 237.73 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Esketamine, sold under the brand name Spravato among others, is a medication used for treatment-resistant depression or depression with acute thoughts of suicide. [1] [4] It; however, appears to be less effective than ketamine. [6] It may also be used for anesthesia and pain. [7] It is used as a nasal spray or by intravenous injection. [1] [7] In depression benefits generally occur within 24 hours. [1]
Common side effects include dissociation, dizziness, sedation, headache, anxiety, vomiting, and increased blood pressure. [1] Other side effects may include misuse. [4] The compound is the S(+) enantiomer of ketamine. [8] Use when breastfeeding is not recommended. [9] It primarily acts by blocking N-methyl-D-aspartate (NMDA) receptors. [1]
Esketamine came into medical use in Germany in 1997. [10] [11] It was approved for medical use in the United States and Europe in 2019. [8] [12] It is available as a generic medication. [13] In the United States the nasal spray costs about 5,500 to 7,900 USD for the first month of treatment as of 2021. [14] [4] The intravenous formulation in the United Kingdom costs the NHS about £26 for 10 vials of 50 mg each. [7]
{{
cite book}}
: CS1 maint: date format (
link)